Ask AI
ProCE Banner Activity

PREFER-LA: Real-world Efficacy of Switch to LA CAB + RPV in People Living With HIV and Adherence Challenges 

Conference Coverage
Slideset

In this real-world, observational study, after switch to LA CAB plus RPV among those with HIV experiencing adherence challenges with daily oral antiretroviral therapy, almost all participants (98%) achieved or maintained HIV-1 RNA ≤200 copies/mL. 

Released: October 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare